In a nutshell This study evaluated whether combining BRAF and MEK inhibitors was safer and more effective than BRAF inhibitor treatment alone for patients with melanoma. This study concluded that combination therapy led to better survival but was associated with certain side effects. Some background Melanoma is a type of skin cancer that can be...
Read MoreMelanoma Posts on Medivizor
Surviving cancer – is there a greater risk of cardiovascular disease long-term?
In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors. They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...
Read MoreEvaluating the safety of smaller excision margins for thick melanomas
In a nutshell This study evaluated the effectiveness of 2 cm versus 4 cm excision margins for patients with thick melanomas on the surface of the skin (cutaneous). This study concluded that a 2-cm excision margin was safe for these patients. Some background The primary treatment for all stages of melanoma is surgery to remove the tumor. This involves...
Read MoreNivolumab in rare melanoma: is it effective in patients that progressed on ipilimumab?
In a nutshell This study investigated if nivolumab (Opdivo) is safe and effective in patients with rare melanoma subtypes (RMS) who progressed after ipilimumab (Yervoy). They found that this treatment was safe and improved survival in certain RMS. Some background Melanoma the most common cancers. There are many subtypes...
Read MoreEvaluating the long-term outcomes of pembrolizumab versus ipilimumab for advanced melanoma
In a nutshell This study compared the long-term outcomes of two targeted therapies for patients with advanced melanoma. This study concluded that pembrolizumab (Keytruda) was more effective than ipilimumab (Yervoy) for these patients, with a similar rate of side effects. Some background Advanced melanoma is a type of skin cancer...
Read MoreLooking for patients with advanced melanoma to test a combination of antibody and enzyme drugs
In a nutshell This trial is examining if adding antibody drug rituximab (Rituxan) and enzyme drug hyaluronidase human (Hycela) can increase the effectiveness of the standard treatment for melanoma. The main outcomes of this trial will be to examine the side effects experienced by patients and tumor response. This study is recruiting in...
Read MoreAtezolizumab, cobimetinib and vemurafenib: a combination for the treatment of BRAF-mutated melanoma
In a nutshell This study investigated atezolizumab (Tecentriq) in combination with cobimetinib (Cotellic) and vemurafenib (Zelboraf) in BRAF-mutated melanoma. They found that this combination is promising and well tolerated in these patients. Some background Melanoma or skin cancer is often by...
Read MoreCombining dabrafenib, trametinib and pembrolizumab for the treatment of BRAF-mutant melanoma
In a nutshell This study investigated the effect of combined dabrafenib (Tafinlar), trametinib (Mekinist) and pembrolizumab (Keytruda) in melanoma. They found that this combination improved survival in advanced melanoma. Some background Melanoma or skin cancer is a common cancer. Genetic mutations can lead to...
Read MoreLooking for participants with metastatic melanoma to test a new immunotherapy
In a nutshell This phase 1 trial is examining the effectiveness of personalized tumor antigens (PTA) in the treatment of different advanced tumors. The main outcomes to be measured will be side effects and disease control. This study is being conducted in Arizona, California, Louisiana and New Jersey, US. The details While the tumor cells are growing,...
Read MoreSearching patients with relapsed or unresponsive cancer to test a new medication
In a nutshell This phase 1b/2 trial will investigate the safety of RMC-4630 and cobimetinib (Cotellic) in relapsed or unresponsive solid tumors. The main outcomes will be the number of side effects and the overall response rate. This trial is recruiting in a number of US states. The details Relapsed/refractory...
Read MoreSearching for patients with melanoma to test a new medication
In a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced melanoma. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details Melanoma or skin cancer is one of the most common cancers. The...
Read MoreSearching for patients with melanoma to test a new medication
In a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced melanoma. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details Melanoma or skin cancer is one of the most common cancers. The...
Read More
